These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 21105778)

  • 1. Human influenza vaccines and assessment of immunogenicity.
    Zakay-Rones Z
    Expert Rev Vaccines; 2010 Dec; 9(12):1423-39. PubMed ID: 21105778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and protective efficacy of an elastase-dependent live attenuated swine influenza virus vaccine administered intranasally in pigs.
    Masic A; Lu X; Li J; Mutwiri GK; Babiuk LA; Brown EG; Zhou Y
    Vaccine; 2010 Oct; 28(43):7098-108. PubMed ID: 20708697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum and mucosal immunologic responses in children following the administration of a new inactivated intranasal anti-influenza vaccine.
    Greenbaum E; Furst A; Kiderman A; Stewart B; Levy R; Schlesinger M; Morag A; Zakay-Rones Z
    J Med Virol; 2001 Sep; 65(1):178-84. PubMed ID: 11505461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A practical influenza neutralization assay to simultaneously quantify hemagglutinin and neuraminidase-inhibiting antibody responses.
    Hassantoufighi A; Zhang H; Sandbulte M; Gao J; Manischewitz J; King L; Golding H; Straight TM; Eichelberger MC
    Vaccine; 2010 Jan; 28(3):790-7. PubMed ID: 19887135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant.
    Vesikari T; Pellegrini M; Karvonen A; Groth N; Borkowski A; O'Hagan DT; Podda A
    Pediatr Infect Dis J; 2009 Jul; 28(7):563-71. PubMed ID: 19561422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mucosal (SIgA) and serum (IgG) immunologic responses in young adults following intranasal administration of one or two doses of inactivated, trivalent anti-influenza vaccine.
    Greenbaum E; Engelhard D; Levy R; Schlezinger M; Morag A; Zakay-Rones Z
    Vaccine; 2004 Jun; 22(20):2566-77. PubMed ID: 15193382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparative study on safety and immunogenicity between influenza subunit vaccine and split vaccine].
    Dong PM; Li YQ; Zheng TZ; Jia YP; Li F; Han TW; Qiao RX; Zhang BH
    Zhonghua Liu Xing Bing Xue Za Zhi; 2003 Jul; 24(7):570-3. PubMed ID: 12975010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial.
    Wu J; Fang HH; Chen JT; Zhou JC; Feng ZJ; Li CG; Qiu YZ; Liu Y; Lu M; Liu LY; Dong SS; Gao Q; Zhang XM; Wang N; Yin WD; Dong XP
    Clin Infect Dis; 2009 Apr; 48(8):1087-95. PubMed ID: 19281330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.
    Treanor JJ; Campbell JD; Zangwill KM; Rowe T; Wolff M
    N Engl J Med; 2006 Mar; 354(13):1343-51. PubMed ID: 16571878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response to a monovalent 2009 influenza A (H1N1) vaccine.
    Greenberg ME; Lai MH; Hartel GF; Wichems CH; Gittleson C; Bennet J; Dawson G; Hu W; Leggio C; Washington D; Basser RL
    N Engl J Med; 2009 Dec; 361(25):2405-13. PubMed ID: 19745216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of adjuvanted inactivated split-virion and whole-virion influenza A (H5N1) vaccines in children: a phase I-II randomized trial.
    Wu J; Liu SZ; Dong SS; Dong XP; Zhang WL; Lu M; Li CG; Zhou JC; Fang HH; Liu Y; Liu LY; Qiu YZ; Gao Q; Zhang XM; Chen JT; Zhong X; Yin WD; Feng ZJ
    Vaccine; 2010 Aug; 28(38):6221-7. PubMed ID: 20638454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
    Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
    Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.
    Bright RA; Carter DM; Daniluk S; Toapanta FR; Ahmad A; Gavrilov V; Massare M; Pushko P; Mytle N; Rowe T; Smith G; Ross TM
    Vaccine; 2007 May; 25(19):3871-8. PubMed ID: 17337102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical experience with inactivated, virosomal influenza vaccine.
    de Bruijn IA; Nauta J; Cramer WC; Gerez L; Palache AM
    Vaccine; 2005 Jul; 23 Suppl 1():S39-49. PubMed ID: 16005120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and protective efficacy of influenza vaccination.
    Hannoun C; Megas F; Piercy J
    Virus Res; 2004 Jul; 103(1-2):133-8. PubMed ID: 15163501
    [No Abstract]   [Full Text] [Related]  

  • 17. Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children.
    Nolan T; Richmond PC; Formica NT; Höschler K; Skeljo MV; Stoney T; McVernon J; Hartel G; Sawlwin DC; Bennet J; Ryan D; Basser RL; Zambon MC
    Vaccine; 2008 Nov; 26(50):6383-91. PubMed ID: 18801398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.
    Leroux-Roels I; Roman F; Forgus S; Maes C; De Boever F; Dramé M; Gillard P; van der Most R; Van Mechelen M; Hanon E; Leroux-Roels G
    Vaccine; 2010 Jan; 28(3):849-57. PubMed ID: 19835828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NEW technologies for meeting the global demand for pandemic influenza vaccines.
    Fedson DS
    Biologicals; 2008 Nov; 36(6):346-9. PubMed ID: 18715803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and safety of intradermal influenza vaccination in healthy older adults.
    Chi RC; Rock MT; Neuzil KM
    Clin Infect Dis; 2010 May; 50(10):1331-8. PubMed ID: 20377407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.